Gene delivery strategies targeting stable atheromatous plaque

Current Pharmaceutical Design

Volumn 19, Issue 9, 2013, Pages 1626-1637

  Van Assche, Tim ^a   Huygelen, Véronique ^a   Crabtree, Mark J ^b   Antoniades, Charalambos ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atheromatous plaque; Gene therapy; Grafts

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; EDIFOLIGIDE; LENTIVIRUS VECTOR; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; NITRIC OXIDE; PARVOVIRUS VECTOR; PLASMID DNA; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA1;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANGINA PECTORIS; ANGIOGENESIS; ANTISENSE THERAPY; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; EX VIVO GENE TRANSFER; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; IN VIVO STUDY; IN-STENT RESTENOSIS; LENTIVIRINAE; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROVIRUS; VIRAL GENE DELIVERY SYSTEM;

EID: 84876710753     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213805219603     Document Type: Article

References (193)

1. Van-Assche T, Huygelen V, Crabtree MJ, Antoniades C. Gene therapy targeting inflammation in atherosclerosis. Curr Pharm Des; 17: 4210-23.
2. Hulsmans M, Holvoet P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med; 14: 70-8.
3. Van Assche T, Huygelen V, Crabtree MJ. Targeting vascular redox biology through antioxidant gene delivery: a historical view and current perspectives. Recent Pat Cardiovasc Drug Discov; 6: 89-102.
4. Antoniades C, Tousoulis D, Tentolouris C, Toutouzas P, Stefanadis C. Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice. Herz 2003; 28: 628-38.
5. Antoniades C, Tousoulis D, Vasiliadou C, et al. Combined effects of smoking and hypercholesterolemia on inflammatory process, thrombosis/fibrinolysis system, and forearm hyperemic response. Am J Cardiol 2004; 94: 1181-4.
6. Campbell JH, Campbell GR. Cell biology of atherosclerosis. J Hypertens Suppl 1994; 12: S129-32.
7. Drakopoulou M, Toutouzas K, Michelongona A, Tousoulis D, Stefanadis C. Vulnerable plaque and inflammation: potential clinical strategies. Curr Pharm Des; 17: 4190-209.
8. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41: 159-68.
9. Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP. Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 2009; 21: 1611-9.
10. Nauta ST, Gaspersz M, Deckers JW. The new European Society of Cardiology guidelines on myocardial revascularisation: an appraisal. Heart; 98: 11-4.
11. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of longacting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849-57.
12. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-75.
13. Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009; 120: 2529-40.
14. Hjemdahl P, Eriksson SV, Held C, et al. Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS). Heart 2006; 92: 177-82.
15. Nair V. Retrovirus-induced oncogenesis and safety of retroviral vectors. Curr Opin Mol Ther 2008; 10: 431-8.
16. Cemazar M, Golzio M, Sersa G, Rols MP, Teissie J. Electricallyassisted nucleic acids delivery to tissues in vivo: where do we stand? Curr Pharm Des 2006; 12: 3817-25.
17. Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy--what have we learned? J Neurooncol 2003; 65: 227-36.
18. Hall K, Blair Zajdel ME, Blair GE. Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy. Biochem J; 431: 321-36.
19. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007; 36: 71-80.
20. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21: 583-93.
21. Tros de Ilarduya C, Sun Y, Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci; 40: 159-70.
22. Budker V, Gurevich V, Hagstrom JE, Bortzov F, Wolff JA. pHsensitive, cationic liposomes: a new synthetic virus-like vector. Nat Biotechnol 1996; 14: 760-4.
23. Shukla N, Jeremy JY. Pathophysiology of saphenous vein graft failure: a brief overview of interventions. Curr Opin Pharmacol.
24. Margaritis M, Channon KM, Antoniades C. Statins and vein graft failure in coronary bypass surgery. Curr Opin Pharmacol.
25. Suzuki J, Isobe M, Morishita R, et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997; 3: 900-3.
26. Bai H, Morishita R, Kida I, et al. Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cellderived inhibitor-1 gene. Gene Ther 1998; 5: 761-9.
27. Wan S, George SJ, Nicklin SA, Yim AP, Baker AH. Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther 2004; 9: 689-98.
28. Lamfers ML, Aalders MC, Grimbergen JM, et al. Adenoviral delivery of a constitutively active retinoblastoma mutant inhibits neointima formation in a human explant model for vein graft disease. Vascul Pharmacol 2002; 39: 293-301.
29. Kritz AB, Yu J, Wright PL, et al. In vivo modulation of Nogo-B attenuates neointima formation. Mol Ther 2008; 16: 1798-804.
30. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998; 9: 867-77.
31. George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 1998; 5: 1552-60.
32. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296-304.
33. George SJ, Wan S, Hu J, et al. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation; 124: S135-42.
34. Eefting D, de Vries MR, Grimbergen JM, et al. In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1. ATF), a cellsurface directed matrix metalloproteinase inhibitor. J Vasc Surg; 51: 429-37.
35. Eefting D, Seghers L, Grimbergen JM, et al. A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Cardiovasc Res; 88: 367-75.
36. Puhakka HL, Turunen P, Gruchala M, et al. Effects of vaccinia virus anti-inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits. In vivo 2005; 19: 515-21.
37. Horiba M, Kadomatsu K, Nakamura E, et al. Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest 2000; 105: 489-95.
38. Banno H, Takei Y, Muramatsu T, Komori K, Kadomatsu K. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg 2006; 44: 633-41.
39. Schepers A, Eefting D, Bonta PI, et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 2006; 26: 2063-9.
40. Wolff RA, Ryomoto M, Stark VE, et al. Antisense to transforming growth factor-beta1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1. J Vasc Surg 2005; 41: 498-508.
41. Ranjzad P, Salem HK, Kingston PA. Adenovirus-mediated gene transfer of fibromodulin inhibits neointimal hyperplasia in an organ culture model of human saphenous vein graft disease. Gene Ther 2009; 16: 1154-62.
42. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84: 9265-9.
43. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
44. Forstermann U, Mugge A, Bode SM, Frolich JC. Response of human coronary arteries to aggregating platelets: importance of endothelium-derived relaxing factor and prostanoids. Circ Res 1988; 63: 306-12.
45. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7.
46. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-8.
47. Matsumoto T, Komori K, Yonemitsu Y, et al. Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg 1998; 27: 135-44.
48. Ohta S, Komori K, Yonemitsu Y, et al. Intraluminal gene transfer of endothelial cell-nitric oxide synthase suppresses intimal hyperplasia of vein grafts in cholesterol-fed rabbit: a limited biological effect as a result of the loss of medial smooth muscle cells. Surgery 2002; 131: 644-53.
49. Wu S, Wang X, Guo L, Zi J. Adenovirus mediated endothelial nitric oxide synthase gene transfer prevents restenosis of vein grafts. ASAIO J 2004; 50: 272-7.
50. Kibbe MR, Tzeng E, Gleixner SL, et al. Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 2001; 34: 156-65.
51. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-8.
52. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005; 294: 2446-54.
53. Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol; 9: 53-62.
54. Jukema JW, Ahmed TA, Verschuren JJ, Quax PH. Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol; 9: 79-90.
55. Klugherz BD, Jones PL, Cui X, et al. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 2000; 18: 1181-4.
56. Perlstein I, Connolly JM, Cui X, et al. DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection. Gene Ther 2003; 10: 1420-8.
57. Takahashi A, Palmer-Opolski M, Smith RC, Walsh K. Transgene delivery of plasmid DNA to smooth muscle cells and macrophages from a biostable polymer-coated stent. Gene Ther 2003; 10: 1471-8.
58. Kim TG, Lee Y, Park TG. Controlled gene-eluting metal stent fabricated by bio-inspired surface modification with hyaluronic acid and deposition of DNA/PEI polyplexes. Int J Pharm; 384: 181-8.
59. Zhu D, Jin X, Leng X, et al. Local gene delivery via endovascular stents coated with dodecylated chitosan-plasmid DNA nanoparticles. Int J Nanomedicine; 5: 1095-102.
60. Klugherz BD, Song C, DeFelice S, et al. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther 2002; 13: 443-54.
61. Zhang LH, Luo T, Zhang C, et al. Anti-DNA antibody modified coronary stent for plasmid gene delivery: results obtained from a porcine coronary stent model. J Gene Med; 13: 37-45.
62. Ye YW, Landau C, Willard JE, et al. Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall. Ann Biomed Eng 1998; 26: 398-408.
63. Nakayama Y, Ji-Youn K, Nishi S, Ueno H, Matsuda T. Development of high-performance stent: gelatinous photogelcoated stent that permits drug delivery and gene transfer. J Biomed Mater Res 2001; 57: 559-66.
64. Byrne RA, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol 2009; 57: 567-84.
65. Fishbein I, Alferiev I, Bakay M, et al. Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation 2008; 117: 2096-103.
66. Panetta CJ, Miyauchi K, Berry D, et al. A tissue-engineered stent for cell-based vascular gene transfer. Hum Gene Ther 2002; 13: 433-41.
67. Yuan J, Gao R, Shi R, et al. Intravascular local gene transfer mediated by protein-coated metallic stent. Chin Med J (Engl) 2001; 114: 1043-5.
68. Egashira K, Nakano K, Ohtani K, et al. Local delivery of antimonocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler Thromb Vasc Biol 2007; 27: 2563-8.
69. Walter DH, Cejna M, Diaz-Sandoval L, et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 2004; 110: 36-45.
70. Takemoto Y, Kawata H, Soeda T, et al. Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis. Arterioscler Thromb Vasc Biol 2009; 29: 857-62.
71. Gertz ZM, Wilensky RL. Local drug delivery for treatment of coronary and peripheral artery disease. Cardiovasc Ther; 29: e54-66.
72. Muhs A, Heublein B, Schletter J, et al. Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation. Hum Gene Ther 2003; 14: 375-83.
73. Wang K, Kessler PD, Zhou Z, et al. Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. Mol Ther 2003; 7: 597-603.
74. Cejna M, Breuss JM, Bergmeister H, et al. Inhibition of neointimal formation after stent placement with adenovirus-mediated gene transfer of I kappa B alpha in the hypercholesterolemic rabbit model: initial results. Radiology 2002; 223: 702-8.
75. Nakano K, Egashira K, Ohtani K, et al. Catheter-based adenovirusmediated anti-monocyte chemoattractant gene therapy attenuates in-stent neointima formation in cynomolgus monkeys. Atherosclerosis 2007; 194: 309-16.
76. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des; 18: 1519-30.
77. Jankowski P, Safar ME, Benetos A. Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. Curr Pharm Des 2009; 15: 571-84.
78. Hayashi T, Sumi D, Juliet PA, et al. Gene transfer of endothelial NO synthase, but not eNOS plus inducible NOS, regressed atherosclerosis in rabbits. Cardiovasc Res 2004; 61: 339-51.
79. Sharif F, Hynes SO, Cooney R, et al. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Mol Ther 2008; 16: 1674-80.
80. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation 1999; 99: 2979-82.
81. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998; 95: 9220-5.
82. Ozaki M, Kawashima S, Yamashita T, et al. Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest 2002; 110: 331-40.
83. Crabtree MJ, Tatham AL, Al-Wakeel Y, et al. Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J Biol Chem 2009; 284: 1136-44.
84. Crabtree MJ, Smith CL, Lam G, Goligorsky MS, Gross SS. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am J Physiol Heart Circ Physiol 2008; 294: H1530-40.
85. Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 2000; 347 Pt 1: 1-16.
86. Doehring A, Antoniades C, Channon KM, Tegeder I, Lotsch J. Clinical genetics of functionally mild non-coding GTP cyclohydrolase 1 (GCH1) polymorphisms modulating pain and cardiovascular risk. Mutat Res 2008; 659: 195-201.
87. Antoniades C, Shirodaria C, Van Assche T, et al. GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J Am Coll Cardiol 2008; 52: 158-65.
88. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 445-50.
89. Ali ZA, Bursill CA, Douglas G, et al. CCR2-mediated antiinflammatory effects of endothelial tetrahydrobiopterin inhibit vascular injury-induced accelerated atherosclerosis. Circulation 2008; 118: S71-7.
90. Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med 1996; 2: 87-90.
91. Platt JL, Nath KA. Heme oxygenase: protective gene or Trojan horse. Nat Med 1998; 4: 1364-5.
92. Johnson F, Giulivi C. Superoxide dismutases and their impact upon human health. Mol Aspects Med 2005; 26: 340-52.
93. Nicholls P. Classical catalase: Ancient and modern. Arch Biochem Biophys.
94. Chen YH, Lin SJ, Lin MW, et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002; 111: 1-8.
95. Kaneda H, Ohno M, Taguchi J, et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002; 22: 1680-5.
96. Gupta S, Sodhi S, Mahajan V. Correlation of antioxidants with lipid peroxidation and lipid profile in patients suffering from coronary artery disease. Expert Opin Ther Targets 2009; 13: 889-94.
97. Hoen PA, Van der Lans CA, Van Eck M, et al. Aorta of ApoEdeficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ Res 2003; 93: 262-9.
98. Juan SH, Lee TS, Tseng KW, et al. Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 104: 1519-25.
99. Bouche D, Chauveau C, Roussel JC, et al. Inhibition of graft arteriosclerosis development in rat aortas following heme oxygenase-1 gene transfer. Transpl Immunol 2002; 9: 235-8.
100. Tulis DA, Durante W, Peyton KJ, Evans AJ, Schafer AI. Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. Atherosclerosis 2001; 155: 113-22.
101. Datla SR, Dusting GJ, Mori TA, et al. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 2007; 50: 636-42.
102. Asija A, Peterson SJ, Stec DE, Abraham NG. Targeting endothelial cells with heme oxygenase-1 gene using VE-cadherin promoter attenuates hyperglycemia-mediated cell injury and apoptosis. Antioxid Redox Signal 2007; 9: 2065-74.
103. Ahmad M, Turkseven S, Mingone CJ, et al. Heme oxygenase-1 gene expression increases vascular relaxation and decreases inducible nitric oxide synthase in diabetic rats. Cell Mol Biol (Noisy-le-grand) 2005; 51: 371-6.
104. Eguchi D, Weiler D, Alam J, Nath K, Katusic ZS. Protective effect of heme oxygenase-1 gene transfer against oxyhemoglobin-induced endothelial dysfunction. J Cereb Blood Flow Metab 2001; 21: 1215-22.
105. Abraham NG, Rezzani R, Rodella L, et al. Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes. Am J Physiol Heart Circ Physiol 2004; 287: H2468-77.
106. Yang H, Roberts LJ, Shi MJ, et al. Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E. Circ Res 2004; 95: 1075-81.
107. Ozumi K, Tasaki H, Takatsu H, et al. Extracellular superoxide dismutase overexpression reduces cuff-induced arterial neointimal formation. Atherosclerosis 2005; 181: 55-62.
108. Brasen JH, Leppanen O, Inkala M, et al. Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta. J Am Coll Cardiol 2007; 50: 2249-53.
109. Zanetti M, Sato J, Jost CJ, et al. Gene transfer of manganese superoxide dismutase reverses vascular dysfunction in the absence but not in the presence of atherosclerotic plaque. Hum Gene Ther 2001; 12: 1407-16.
110. Laukkanen MO, Leppanen P, Turunen P, et al. Gene transfer of extracellular superoxide dismutase to atherosclerotic mice. Antioxid Redox Signal 2001; 3: 397-402.
111. Durand E, Al Haj Zen A, Addad F, et al. Adenovirus-mediated gene transfer of superoxide dismutase and catalase decreases restenosis after balloon angioplasty. J Vasc Res 2005; 42: 255-65.
112. Johnsen SH, Mathiesen EB, Fosse E, et al. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromso study. Circulation 2005; 112: 498-504.
113. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15: 2073-84.
114. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273: 6088-95.
115. Garner B, Witting PK, Waldeck AR, et al. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem 1998; 273: 6080-7.
116. Mertens A, Verhamme P, Bielicki JK, et al. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003; 107: 1640-6.
117. Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2495-500.
118. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
119. Feng Y, Van Craeyveld E, Jacobs F, et al. Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. J Mol Med (Berl) 2009; 87: 287-97.
120. Pastore L, Belalcazar LM, Oka K, et al. Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene 2004; 327: 153-60.
121. Zhang C, Peng W, Wang M, et al. Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice. Gene Ther; 17: 626-33.
122. Ng CJ, Hama SY, Bourquard N, Navab M, Reddy ST. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol Genet Metab 2006; 89: 368-73.
123. Ng CJ, Bourquard N, Hama SY, et al. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 1368-74.
124. Belalcazar LM, Merched A, Carr B, et al. Long-term stable expression of human apolipoprotein A-I mediated by helperdependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003; 107: 2726-32.
125. Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100: 1816-22.
126. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1545-50.
127. Miyoshi M, Nakano Y, Sakaguchi T, et al. Gene delivery of paraoxonase-1 inhibits neointimal hyperplasia after arterial balloon-injury in rabbits fed a high-fat diet. Hypertens Res 2007; 30: 85-91.
128. Guns PJ, Van Assche T, Verreth W, et al. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Br J Pharmacol 2008; 153: 508-16.
129. Van Craeyveld E, Lievens J, Jacobs F, et al. Apolipoprotein A-I and lecithin:cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions. Gene Ther 2009; 16: 757-65.
130. Hoeg JM, Santamarina-Fojo S, Berard AM, et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A 1996; 93: 11448-53.
131. Smith RM, Wu GY. Hepatocyte-directed gene delivery by receptor-mediated endocytosis. Semin Liver Dis 1999; 19: 83-92.
132. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004; 61: 671-82.
133. Kitamoto S, Egashira K. Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases. Expert Rev Cardiovasc Ther 2003; 1: 393-400.
134. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001; 104: 503-16.
135. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
136. Wakkach A, Cottrez F, Groux H. Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw 2000; 11: 153-60.
137. Yoshimura S, Morishita R, Hayashi K, et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 2001; 8: 1635-42.
138. Zhang YJ, Rutledge BJ, Rollins BJ. Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. J Biol Chem 1994; 269: 15918-24.
139. Usui M, Egashira K, Ohtani K, et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J 2002; 16: 1838-40.
140. Ni W, Egashira K, Kitamoto S, et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001; 103: 2096-101.
141. Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002; 106: 2700-6.
142. Egashira K, Zhao Q, Kataoka C, et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002; 90: 1167-72.
143. Ohtani K, Usui M, Nakano K, et al. Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther 2004; 11: 1273-82.
144. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res; 86: 192-201.
145. Burns JM, Dairaghi DJ, Deitz M, Tsang M, Schall TJ. Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics. J Biol Chem 2002; 277: 2785-9.
146. Smith CA, Smith TD, Smolak PJ, et al. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 1997; 236: 316-27.
147. Bursill CA, Choudhury RP, Ali Z, Greaves DR, Channon KM. Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation 2004; 110: 2460-6.
148. Ali ZA, Bursill CA, Hu Y, et al. Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112: I235-41.
149. Bursill CA, McNeill E, Wang L, et al. Lentiviral gene transfer to reduce atherosclerosis progression by long-term CC-chemokine inhibition. Gene Ther 2009; 16: 93-102.
150. Lim S, Ahn BY, Chung SS, et al. Effect of a peroxisome proliferator-activated receptor gamma sumoylation mutant on neointimal formation after balloon injury in rats. Atherosclerosis 2009; 206: 411-7.
151. Yoshioka T, Okada T, Maeda Y, et al. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther 2004; 11: 1772-9.
152. Namiki M, Kawashima S, Yamashita T, et al. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004; 172: 21-9.
153. Liu Y, Li D, Chen J, et al. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 2006; 188: 19-27.
154. Han X, Kitamoto S, Wang H, Boisvert WA. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J; 24: 2869-80.
155. Khan JA, Cao M, Kang BY, et al. AAV/hSTAT3-gene delivery lowers aortic inflammatory cell infiltration in LDLR KO mice on high cholesterol. Atherosclerosis; 213: 59-66.
156. Li D, Liu Y, Chen J, et al. Suppression of atherogenesis by delivery of TGFbeta1ACT using adeno-associated virus type 2 in LDLR knockout mice. Biochem Biophys Res Commun 2006; 344: 701-7.
157. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223-61.
158. Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386: 292-6.
159. Babaev VR, Gleaves LA, Carter KJ, et al. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol 2000; 20: 2593-9.
160. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 1049-56.
161. Mehta JL, Sanada N, Hu CP, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007; 100: 1634-42.
162. Febbraio M, Guy E, Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 2333-8.
163. Zhang L, Liu HJ, Li TJ, et al. Lentiviral vector-mediated siRNA knockdown of SR-PSOX inhibits foam cell formation in vitro. Acta Pharmacol Sin 2008; 29: 847-52.
164. Ishigaki Y, Katagiri H, Gao J, et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 2008; 118: 75-83.
165. Jalkanen J, Leppanen P, Narvanen O, Greaves DR, Yla-Herttuala S. Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knockout mice. Atherosclerosis 2003; 169: 95-103.
166. Jalkanen J, Leppanen P, Pajusola K, et al. Adeno-associated virusmediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice. Mol Ther 2003; 8: 903-10.
167. Laukkanen J, Lehtolainen P, Gough PJ, et al. Adenovirus-mediated gene transfer of a secreted form of human macrophage scavenger receptor inhibits modified low-density lipoprotein degradation and foam-cell formation in macrophages. Circulation 2000; 101: 1091-6.
168. Murase T, Kume N, Kataoka H, et al. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol 2000; 20: 715-20.
169. Lahteenvuo JE, Lahteenvuo MT, Kivela A, et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation 2009; 119: 845-56.
170. Atluri P, Woo YJ. Pro-angiogenic cytokines as cardiovascular therapeutics: assessing the potential. BioDrugs 2008; 22: 209-22.
171. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-4.
172. Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999; 68: 830-6; discussion 836-7.
173. Sarkar N, Ruck A, Kallner G, et al. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy. J Intern Med 2001; 250: 373-81.
174. Stewart DJ, Kutryk MJ, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009; 17: 1109-15.
175. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-74.
176. Fuchs S, Dib N, Cohen BM, et al. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease. Catheter Cardiovasc Interv 2006; 68: 372-8.
177. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and instent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677-83.
178. Hedman M, Muona K, Hedman A, et al. Eight-year safety followup of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 2009; 16: 629-34.
179. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291-7.
180. Yuan B, Zhao Z, Zhang YR, et al. Short-term safety and curative effect of recombinant adenovirus carrying hepatocyte growth factor gene on ischemic cardiac disease. In vivo 2008; 22: 629-32.
181. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11 Suppl 1: S10-7.
182. Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6: 1574-83.
183. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008; 15: 808-16.
184. Anliker B, Abel T, Kneissl S, et al. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods; 7: 929-35.
185. White K, Buning H, Kritz A, et al. Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther 2008; 15: 443-51.
186. Chorny M, Hood E, Levy RJ, Muzykantov VR. Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J Control Release; 146: 144-51.
187. Hofmann A, Wenzel D, Becher UM, et al. Combined targeting of lentiviral vectors and positioning of transduced cells by magnetic nanoparticles. Proc Natl Acad Sci U S A 2009; 106: 44-9.
188. Mannell H, Pircher J, Rathel T, et al. Targeted endothelial gene delivery by ultrasonic destruction of magnetic microbubbles carrying lentiviral vectors. Pharm Res; 29: 1282-94.
189. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000; 102: 965-74.
190. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006; 13: 1503-11.
191. Kastrup J, Jorgensen E, Fuchs S, et al. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention; 6: 813-8.
192. Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999; 230: 466-70; discussion 470-2.
193. Yang ZJ, Zhang YR, Chen B, et al. Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Mol Biol Rep 2009; 36: 1323-9.